Subthreshold Micropulse Laser Treatment of Acute Central Serous Chorioretinopathy

Not Applicable

Completed

• Conditions: Acute Central Serous Retinopathy With Subretinal Fluid

• Registration Number: NCT05447117
• Lead Sponsor: Minia University

Brief Summary

To evaluate the efficacy and safety of 532 nm green subthreshold micropulse laser (GSML) as a treatment for acute central serous chorioretinopathy (CSCR).

Detailed Description

This prospective study included 42 eyes of 42 patients with acute CSCR treated with IRIDEX™ IQ 532 nm GSML. The study was conducted at Minia University Hospital and Genaidy Ophthalmology Center, Minia, Egypt between October 2019 and May 2022. All patients were subjected to a complete ophthalmological examination, fluorescein angiography (FA) and optical coherence tomography (OCT) at baseline and each follow-up visit 1, 3 and 18 months after laser treatment

Study Timeline

• Study Start: 2019-10-15
• Primary Completion: 2022-05-30
• Study Completion: 2022-06-30
• Study First Submitted: 2022-07-03
• Study First Submitted QC: 2022-07-03
• Study First Posted: 2022-07-07
• Status Verified: 2022-09
• Last Update Submitted: 2022-09-08
• Last Update Posted: 2022-09-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

• acute CSCR

Exclusion Criteria

• chronic CSCR Previously treated case of Acute CSCR

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
change in visual acuity	18 months	resolution of subretinal fluid

Trial Locations

Locations (1)

Minia University Hospital; 🇪🇬 Minya, Minia, Egypt